ECM
CRBP icon

ExodusPoint Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

ExodusPoint Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-116,271
Closed -$5.26M – 1693
2024
Q2 		$5.26M Buy
+116,271
New +$4.89M 0.04% 390
2023
Q1 		– Sell
-562
Closed -$2K – 1806
2022
Q4 		$2K Sell
562
-11,523
-95% -$44.3K ﹤0.01% 1575
2022
Q3 		$60K Buy
+12,085
New +$85.2K ﹤0.01% 1788
2021
Q4 		– Sell
-3,124
Closed -$96K – 2218
2021
Q3 		$96K Buy
3,124
+704
+29% +$27.8K ﹤0.01% 1911
2021
Q2 		$133K Buy
2,420
+1,153
+91% +$64K ﹤0.01% 2089
2021
Q1 		$75K Buy
+1,267
New +$83.3K ﹤0.01% 2005
2020
Q3 		– Sell
-379
Closed -$95K – 1815
2020
Q2 		$95K Buy
+379
New +$76.6K ﹤0.01% 1636
2020
Q1 		– Sell
-363
Closed -$59K – 1156
2019
Q4 		$59K Buy
+363
New +$53.6K ﹤0.01% 1449
2019
Q3 		– Sell
-636
Closed -$132K – 1376
2019
Q2 		$132K Buy
+636
New +$136K 0.01% 993

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

ExodusPoint Capital Management's CRBP Position: Q3 2024 in Review

ExodusPoint Capital Management sold out of Corbus Pharmaceuticals (CRBP) in Q3 2024, closing a stake of 116,271 shares — an estimated $5.26M sold.

ExodusPoint Capital Management first reported a position in CRBP in Q2 2019 and held it in 9 quarters. The position peaked at $5.26M in Q2 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q3 2024.

  • ExodusPoint Capital Management reported no remaining Corbus Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • ExodusPoint Capital Management sold 116,271 Corbus Pharmaceuticals shares in Q3 2024, an estimated $5.26M.
  • ExodusPoint Capital Management first reported a position in Corbus Pharmaceuticals in Q2 2019 and held it in 9 quarters.
  • ExodusPoint Capital Management's Corbus Pharmaceuticals position peaked at $5.26M in Q2 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2024.

Based on ExodusPoint Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.